7.4 million Americans could gain Medicare or Medicaid coverage for anti-obesity drugs under Biden proposal

Contributing sentiments towards policy:

53% : The coverage expansion could wind up costing Medicare nearly $3 billion a year and contribute to higher Part D premiums for all beneficiaries, the KFF analysis found.Fully expanding GLP-1 coverage to Medicare enrollees with obesity or overweight would cost $35 billion over nine years, while the savings from their improved health would be small, according to a recent report from the Congressional Budget Office.
51% : But the Centers for Medicare and Medicaid Services opened the door to coverage of Wegovy for Medicare enrollees in March after the US Food and Drug Administration approved the drug for adults with cardiovascular disease who are either obese or overweight.
42% : Medicare is prohibited by law from covering drugs for obesity.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.